By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Histone deacetylase inhibitors > Romidepsin > Romidepsin Dosage
Histone deacetylase inhibitors
https://themeditary.com/dosage-information/romidepsin-dosage-6673.html

Romidepsin Dosage

Drug Detail:Romidepsin (Romidepsin [ roe-mi-dep-sin ])

Drug Class: Histone deacetylase inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Cutaneous T-cell Lymphoma

14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 28-day cycle; repeat cycle every 28 days provided patient continues to benefit and is tolerating therapy

Uses: For the treatment of cutaneous T-cell Lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least 1 prior systemic therapy.

Usual Adult Dose for Peripheral T-cell Lymphoma

14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 28-day cycle; repeat cycle every 28 days provided patient continues to benefit and is tolerating therapy

Uses: For the treatment of cutaneous T-cell Lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least 1 prior systemic therapy.

Renal Dose Adjustments

Use with caution in patients with end stage renal disease (ESRD).

Liver Dose Adjustments

Mild hepatic impairment: No adjustment recommended.
Moderate hepatic impairment (bilirubin greater than 1.5 x upper limit of normal [ULN] to 3 x ULN or less): Reduce dose to 7 mg/m2.
Severe hepatic impairment (bilirubin greater than 3 x ULN): Reduce dose to 5 mg/2.

Dose Adjustments

NONHEMATOLOGIC TOXICITIES (EXCEPT ALOPECIA):

  • Grade 2 or 3: Delay therapy until toxicity returns to Grade 1 or less or baseline; resume at 14 mg/m2.
  • Grade 3 recurrence: Delay therapy until toxicity returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2.
  • Grade 4: Delay therapy until toxicity returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2.
  • Grade 3 or 4 recurrence after dose reduction: Discontinue therapy.

HEMATOLOGIC TOXICITIES:
  • Grade 3 or 4 neutropenia or thrombocytopenia: Delay therapy until specific cytopenia returns to absolute neutrophil count (ANC) of 1.5 x 10(9)/L or greater and/or platelet count is 75 x 10(9)/L or baseline; restart at 14 mg/m2.
  • Grade 4 febrile (38.5C or greater) neutropenia or thrombocytopenia requiring platelet transfusion: Delay therapy until specific cytopenia returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2.

Precautions

CONTRAINDICATIONS:

  • None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Administer IV over a 4-hour period.
  • Nausea and vomiting are commonly reported; consider antiemetic support.

Storage requirements:
  • This drug is supplied as a kit containing 2 vials in a single carton.
  • Store carton at 20C to 25C; excursions permitted between 15C to 30C.

Reconstitution/preparation techniques:
  • Preparation, handling, and disposal should be handled in a manner consistent with safe procedures and handling for cytotoxic drugs.

General:
  • Reconstituted solution (5 mg/mL) is chemically stable for up to 8 hours at room temperature.
  • Diluted solution is chemically stable for up to 24 hours at room temperature; however, administration as soon as possible following dilution is advised.
  • Prolongation of PT and elevation of INR were observed in a patient receiving this drug concomitantly with warfarin. Monitor PT and INR more frequently in these patients.
  • Strong CYP450 3A4 inhibitors increase concentrations of this drug. Monitor for toxicity related to increased exposure to this drug and follow the dose modifications for toxicity.
  • Rifampin (a potent CYP450 3A4 inducer) increases the concentrations of this drug. Avoid coadministration of this drug with rifampin. The use of other potent CYP450 3A4 inducers should be avoided when possible.

Monitoring:
  • Perform ECG at baseline and periodically, especially in patients with a history of significant cardiovascular disease, those on concomitant QT interval prolonging drugs, or those receiving antiarrhythmic drugs.
  • Verify normal serum potassium and magnesium levels prior to initiating treatment, and periodically during therapy, especially in higher risk patients.
  • Monitor for thrombocytopenia, anemia, neutropenia and lymphopenia during therapy; modify treatment as necessary.
  • Monitor patients with advanced stage disease and/or high tumor burden; institute precautions and treat as needed.

Patient advice:
  • Report nausea and vomiting to your healthcare provider.
  • This drug can lower blood counts and lower resistance to infection; contact your healthcare provider immediately if you experience with signs of infection, significant fatigue, or bleeding.
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by